PrimeRFP SCOUT · Federal Contract Recompete Brief

36C26122N0385Pylarify (piflufolastat f18) NDC: 71258-0022-01 — Progenics Pharmaceuticals, Inc

Progenics Pharmaceuticals, Inc holds $95.0M across 149 federal awards, concentrated at Department of Veterans Affairs (VA). This PIID sits alongside 5 related awards under parent 36F79719D0170. The prior award was single-bid — competitive dynamics may favor a challenge. Recompete timing centers on the Sep 30, 2026 PoP end — agencies typically plan 12–18 months ahead.

261-Network Contract Office 21 (36C261)

Awarding office

Progenics Pharmaceuticals, Inc

Recipient

Sep 30, 2026

PoP end

$4.5M

Obligated

$9.3M

Potential

325412

NAICS

6505

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Progenics Pharmaceuticals, Inc — $90

Contract facts

Federal

Contract number36C26122N0385

Also listed as36C261-22-N-0385

Also listed as36F79719D0170-36C26122N0385

Agency261-Network Contract Office 21 (36C261)

Awarding office261-Network Contract Office 21 (36C261)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentProgenics Pharmaceuticals, Inc

CAGE34KE9

UEIYLYKVRPCTCR3

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79719D0170

Place of performanceNEW YORK NY

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

Related solicitation36C26122Q0288

PoP startMar 30, 2022

PoP end (current)Sep 30, 2026

Obligated$4.5M

Current value$4.5M

Potential value$9.3M

PYLARIFY (PIFLUFOLASTAT F18) NDC: 71258-0022-01 is a federal award for 261-Network Contract Office 21 (36C261) held by Progenics Pharmaceuticals, Inc. Estimated value $9.3M ($4.5M obligated). Current period of performance ends Sep 30, 2026. Last award drew 1 bidder. Place of performance: NEW YORK NY. Related solicitation 36C26122Q0288.

PYLARIFY (PIFLUFOLASTAT F18) NDC: 71258-0022-01

Recompete timing

Public

● Expiring in 40 days

Current PoP ends Sep 30, 2026 (40 days remaining). Agencies typically plan 12–18 months ahead — at 1.3 months out, that window is already open. The buying decision is likely already in motion.

Incumbent footprint

Public record

Progenics Pharmaceuticals, Inc — $95.0M obligated across 149 awards (firm-wide, all agencies) · lead buyer Department of Veterans Affairs (VA).

% of firm-wide obligated ($95.0M) · all agencies

Department of Veterans Affairs (VA)$93.8M · 99%Department of Health and Human Services (HHS)$1.1M · 1%Department of Defense (DOD)$105K · 0%

Open full company profile →

Related awards

Same parent · incumbent

36C24625N1142

PYLARIFY F-18 INJECTIONS (336)

$1.2M

Aug 31, 2026

75N90025F00021

PIFLUFOLASTAT F-18 INJECTION DRUGS (PYLARIFY) FROM SOFIE CO.:1108959 [25-004297]

$611K

Sep 25, 2026

36C26126N0023

480 F18 PYLARIFY DOSES POP 1/1/2025 - 12/31/2025

$1.7M

Sep 26, 2026

75N90025F00003

PIFLUFOLASTAT F-18 INJECTION DRUGS (PYLARIFY) FROM SOFIE CO. [POTS 25-000073]

$2.1M

Sep 29, 2026

36C24826N0071

PYLARIFY (PIFLUFOLASTAT F 18) INJECTION

$1.2M

Sep 30, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C26122N0385?

36C26122N0385 (Pylarify (piflufolastat f18) NDC: 71258-0022-01) is a 261-Network Contract Office 21 (36C261) award with a potential value of $9.3M, currently held by Progenics Pharmaceuticals, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C261-22-N-0385?

36C261-22-N-0385 is the dashed form of PIID 36C26122N0385 (Pylarify (piflufolastat f18) NDC: 71258-0022-01), held by Progenics Pharmaceuticals, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C26122N0385?

261-Network Contract Office 21 (36C261) awarded 36C26122N0385 to Progenics Pharmaceuticals, Inc (potential $9.3M).

Who is the incumbent on 36C26122N0385?

Progenics Pharmaceuticals, Inc is the incumbent with $95.0M across 149 related awards in SCOUT’s public footprint. The current period of performance ends Sep 30, 2026.

When does Progenics Pharmaceuticals, Inc’s 36C26122N0385 come up for recompete?

SCOUT tracks a period-of-performance end of Sep 30, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Jul 2, 2026 · refreshed monthlyLatest procurement action Oct 1, 2025